France Cell Therapy Market Forecast 2022-2028

The France cell therapy market growth is expected to progress at a CAGR of 15.92% during the forecast period, 2022-2028. The France market growth prospects are attributed to the presence of leading research and biotech companies working in the cell therapies segment.

MARKET INSIGHTS

Europe is the second-largest gene and cell therapy market globally, with the UK and France in the top positions. France's biotech industry continues to contribute to the development of gene therapy and cell therapy fields, rendering it conducive to market competition with regard to cell therapies. For instance, Cell-Easy, a start-up in Toulouse specializing in stem cell therapy, collaborated with the University Hospital Centre in Toulouse, procuring the authorization to open a pharmaceutical manufacturing plant for the production of stem cells.

Further, biotechnology companies in France are increasingly prioritizing research activities in the central nervous system, infectious diseases, and oncology. Additionally, many France-based companies are engaged in expanding their businesses related to cell therapy. For instance, TreeFrog Therapeutics opened its first 1300 sq ft facility in June 2020 to scale up cell therapy manufacturing processes based on the induced pluripotent stem(iPS) in Bordeaux, France. As a result, the thriving biotechnology industry is propelling the France cell therapy market growth.

COMPETITIVE INSIGHTS

Some of the prominent firms in the market include: Cellectis, TreeFrog Therapeutics, Bristol Myers Squibb Company, TheraVectys, Sangamo Therapeutics Inc, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 48740

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. KEY GROWTH ENABLERS
2.5. KEY CHALLENGES

3. KEY ANALYTICS

3.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
3.2. PESTLE ANALYSIS
- 3.2.1. POLITICAL
- 3.2.2. ECONOMICAL
- 3.2.3. SOCIAL
- 3.2.4. TECHNOLOGICAL
- 3.2.5. LEGAL
- 3.2.6. ENVIRONMENTAL
3.3. KEY MARKET TRENDS
3.4. PORTER'S FIVE FORCES ANALYSIS
- 3.4.1. BUYERS POWER
- 3.4.2. SUPPLIERS POWER
- 3.4.3. SUBSTITUTION
- 3.4.4. NEW ENTRANTS
- 3.4.5. INDUSTRY RIVALRY
3.5. REGULATORY FRAMEWORK
3.6. OPPORTUNITY MATRIX

4. MARKET BY CELL TYPE

4.1. STEM CELL
- 4.1.1. BONE MARROW
- 4.1.2. BLOOD
- 4.1.3. UMBILICAL CORD-DERIVED STEM CELL
- 4.1.4. ADIPOSE-DERIVED STEM CELL
- 4.1.5. OTHERS
4.2. NON-STEM CELL

5. MARKET BY THERAPY TYPE

5.1. AUTOLOGOUS
5.2. ALLOGENEIC

6. MARKET BY THERAPEUTIC APPLICATION

6.1. MALIGNANCIES
6.2. MUSCULOSKELETAL DISORDERS
6.3. AUTOIMMUNE DISORDERS
6.4. DERMATOLOGY
6.5. OTHER APPLICATIONS

7. MARKET BY END-USER

7.1. HOSPITALS & CLINICS
7.2. ACADEMIC & RESEARCH INSTITUTES

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. MERGERS & ACQUISITIONS
- 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.3. PARTNERSHIPS & AGREEMENTS
- 8.1.4. BUSINESS EXPANSIONS
8.2. COMPANY PROFILES
- 8.2.1. BRISTOL MYERS SQUIBB COMPANY
- 8.2.2. CELLECTIS
- 8.2.3. SANGAMO THERAPEUTICS INC
- 8.2.4. THERAVECTYS
- 8.2.5. TREEFROG THERAPEUTICS

Product Code: 48740

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - CELL THERAPY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: FRANCE CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: FRANCE CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 5: FRANCE CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: FRANCE CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 7: FRANCE CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: FRANCE CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 9: FRANCE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: FRANCE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 11: FRANCE CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: FRANCE CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 13: LIST OF MERGERS & ACQUISITIONS
TABLE 14: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 15: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 16: LIST OF BUSINESS EXPANSIONS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: FRANCE CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021
FIGURE 5: FRANCE CELL THERAPY MARKET, BY STEM CELL, 2022-2028 (IN $ MILLION)
FIGURE 6: FRANCE CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021
FIGURE 7: FRANCE CELL THERAPY MARKET, BY BONE MARROW, 2022-2028 (IN $ MILLION)
FIGURE 8: FRANCE CELL THERAPY MARKET, BY BLOOD, 2022-2028 (IN $ MILLION)
FIGURE 9: FRANCE CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2028 (IN $ MILLION)
FIGURE 10: FRANCE CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2028 (IN $ MILLION)
FIGURE 11: FRANCE CELL THERAPY MARKET, BY OTHERS, 2022-2028 (IN $ MILLION)
FIGURE 12: FRANCE CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2028 (IN $ MILLION)
FIGURE 13: FRANCE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021
FIGURE 14: FRANCE CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2028 (IN $ MILLION)
FIGURE 15: FRANCE CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2028 (IN $ MILLION)
FIGURE 16: FRANCE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021
FIGURE 17: FRANCE CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2028 (IN $ MILLION)
FIGURE 18: FRANCE CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2028 (IN $ MILLION)
FIGURE 19: FRANCE CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2028 (IN $ MILLION)
FIGURE 20: FRANCE CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 21: FRANCE CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 22: FRANCE CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 23: FRANCE CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 24: FRANCE CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2028 (IN $ MILLION)